ScoreWhy is Suzhou Zelgen Biopharmaceuticals Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 92.64% and Operating profit at 5.14% over the last 5 years
3
The company has declared Positive results for the last 4 consecutive quarters
- NET SALES(Q) Highest at CNY 217.79 MM
- RAW MATERIAL COST(Y) Fallen by -9.19% (YoY)
- DEBTORS TURNOVER RATIO(HY) Highest at 4.49 times
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -8.31%, its profits have risen by 43.2%
5
Underperformed the market in the last 1 year
- Even though the market (China Shanghai Composite) has generated returns of 22.49% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -8.31% returns
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Suzhou Zelgen Biopharmaceuticals Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Suzhou Zelgen Biopharmaceuticals Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
-21.07%
0.69
57.63%
China Shanghai Composite
21.43%
1.58
14.20%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
124.93%
EBIT Growth (5y)
25.04%
EBIT to Interest (avg)
-113.20
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.92
Sales to Capital Employed (avg)
0.27
Tax Ratio
3.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
47
Industry P/E
Price to Book Value
13.48
EV to EBIT
48.17
EV to EBITDA
44.09
EV to Capital Employed
366.64
EV to Sales
13.85
PEG Ratio
0.10
Dividend Yield
NA
ROCE (Latest)
761.20%
ROE (Latest)
28.92%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend46What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 856.25 MM
ROCE(HY)
Highest at 33.88%
DEBTORS TURNOVER RATIO(HY)
Highest at 8.89 times
RAW MATERIAL COST(Y)
Fallen by -19.98% (YoY
CASH AND EQV(HY)
Highest at CNY 4,714.82 MM
NET SALES(Q)
Highest at CNY 905.39 MM
OPERATING PROFIT(Q)
Highest at CNY 630.03 MM
OPERATING PROFIT MARGIN(Q)
Highest at 69.59 %
PRE-TAX PROFIT(Q)
Highest at CNY 631.22 MM
NET PROFIT(Q)
Highest at CNY 632.06 MM
EPS(Q)
Highest at CNY 2.39
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Net Sales
At CNY 905.39 MM has Grown at 440.07%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (CNY MM)
Pre-Tax Profit
At CNY 631.22 MM has Grown at 2,182.05%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 632.06 MM has Grown at 2,336.41%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Operating Cash Flow
Highest at CNY 856.25 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Debtors Turnover Ratio
Highest at 8.89 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
Highest at CNY 905.39 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Profit
Highest at CNY 630.03 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 69.59 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY 631.22 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY 632.06 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY 2.39
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Cash and Eqv
Highest at CNY 4,714.82 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by -19.98% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Non Operating Income
Highest at CNY 0.01 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
